Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
NCT ID: NCT04823377
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
364 participants
INTERVENTIONAL
2021-09-24
2027-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility of Supportive Care Needs in Patients With Advanced Solid Cancer in a Therapeutic Trial
NCT04896099
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
NCT04339218
Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT00776100
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
NCT04073745
Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial
NCT01138722
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. clinical parameters;
2. doctors' expectations regarding the continuation of anticancer treatment;
3. patient expectations and preferences;
4. the possibility of referring the patient to a supportive care specialist and strengthening home care.
The process triggers a dialogue between the patient and the oncologist, based on facts and seeks objectivity, ultimately allowing a shared decision.
In this prospective comparative study, the rate of systemic oncological treatment during the last month of life will be measured consecutively, over a period of usual management, followed by a period of systematic application of a process of optimization of the medical decision.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Period A: Usual management
Period of end-of-life care as usual
Usual care
Patients receiving systemic anticancer treatment in their last days of life
Period B: Process of optimization of the medical decision
Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
Optimization of the medical decision
Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Usual care
Patients receiving systemic anticancer treatment in their last days of life
Optimization of the medical decision
Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015)
3. Patient having completed at least one line of chemotherapy in the context of metastatic disease (or in the context of locoregional disease if the last chemotherapy was less than 6 months ago).
4. ECOG Performance Status ≥ 2.
5. Age ≥ 18.
6. Written informed consent.
7. Patient capable, according to the investigator, to comply with the requirements of the study.
Exclusion Criteria
2. Patient with NSCLC for whom a decision has already been made to permanently discontinue all systemic cancer treatment.
3. Impossible follow up for geographical, social or psychological reason.
4. Inability to answer a questionnaire (language or neurological barrier).
5. Patient under guardianship.
6. Patient being treated in a therapeutic trial.
7. Patient not covered by social security. -
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Curie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Ange MASSIANI, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Curie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH Abbeville
Abbeville, , France
CH du Pays d'Aix
Aix-en-Provence, , France
CHU Amiens - Hôpital Sud
Amiens, , France
CHU Angers
Angers, , France
CHR Metz-Thionville - Hôpital de Mercy
Ars-Laquenexy, , France
CH Henri Duffaut Avignon
Avignon, , France
Institut Sainte-Catherine
Avignon, , France
AP-HP Ambroise Paré
Boulogne-Billancourt, , France
CHI de Compiègne-Noyon
Compiègne, , France
CHU Sud Francilien
Corbeil-Essonnes, , France
Clinique des Cèdres
Cornebarrieu, , France
CH Intercommunal de Créteil
Créteil, , France
CGFL
Dijon, , France
CHU Grenoble Alpes
Grenoble, , France
CHD Vendée
La Roche-sur-Yon, , France
CHRU Lille
Lille, , France
Centre Léon Bérard
Lyon, , France
Institut Curie
Paris, , France
AP-HP Cochin
Paris, , France
AP-HP Bichat
Paris, , France
AP-HP Tenon
Paris, , France
Institut Curie
Saint-Cloud, , France
CH Saint-Malo
St-Malo, , France
Hôpital Foch
Suresnes, , France
Clinique Tessier
Valenciennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC 2020-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.